Skip to NavigationSkip to content


EMA under fire from European Parliament

European Parliament
MEPs highlighted conflicts of interest and the independence of the regulator's drug evaluation experts

The EMA has been hit by a barrage of criticism from the European Parliament over conflicts of interest and the independence of its drug evaluation experts.

MEPs said there were no proper guarantees of the independence of experts hired to carry out scientific evaluations of medicines and that some of those evaluating Servier’s diabetes drug Mediator (benfluorex) had conflicting interests.

The damning report also voiced grave concerns with the European regulator’s management of procurement procedures and its lack of criteria for recruiting staff.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches